UD TGFbetai NK cells / The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) - LARVOL DELTA

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Brittany Dulmage | Not yet recruiting ➔ Recruiting

Enrollment open • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Nodular Basal Cell Carcinoma • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Kari Kendra | Trial completion date: Jul 2025 ➔ Nov 2025 | Trial primary completion date: Jul 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Brittany Dulmage

New P1 trial • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Nodular Basal Cell Carcinoma • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Elvira Umyarova | Trial completion date: Dec 2024 ➔ Aug 2025 | Trial primary completion date: Dec 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Kari Kendra | Trial completion date: Dec 2025 ➔ Jul 2025 | Trial primary completion date: Dec 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • TGFB1

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells with or Without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: Margaret Gatti-Mays | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Tumor mutational burden • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • HER-2

NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Elvira Umyarova | Not yet recruiting ➔ Recruiting

Enrollment open • Immune cell • Hematological Malignancies • Multiple Myeloma • Oncology

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Elvira Umyarova

Immune cell • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: Margaret Gatti-Mays

New P1/2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • HER-2

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: Margaret Gatti-Mays | Phase classification: P1b/2 ➔ P1/2

Phase classification • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • HER-2

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer (clinicaltrials.gov) - P1b/2 | N=42 | Recruiting | Sponsor: Margaret Gatti-Mays | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Tumor mutational burden • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • HER-2 • TGFBI

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Kari Kendra | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Preclinical • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • TGFB1